🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Mason Hawkins’s REGN Holdings & Trades

First Buy
Q1 2025
Duration Held
5 Quarters
Largest Add
Q1 2025
+114,880 Shares
Current Position
130,662 Shares
$100.95 M Value

Mason Hawkins's REGN Position Overview

Mason Hawkins (via Southeastern Asset Management Inc/Tn/) currently holds 130,662 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $100.95 M, representing 4.97% of the portfolio. First purchased in 2025-Q1, this short-term holding has been held for 5 quarters.

Based on 13F filings, Mason Hawkins has maintained this position in REGN for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 45,701 shares. Largest reduction occurred in Q1 2026, reducing 35,130 shares.

Analysis based on 13F filings available since 2013 Q2

Mason Hawkins's Regeneron Pharmaceuticals (REGN) Holding Value Over Time

Track share changes against reported price movement

Quarterly Regeneron Pharmaceuticals (REGN) Trades by Mason Hawkins

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 -35,130 Reduce 21.19% 130,662 $772.64
Q4 2025 +21,185 Add 14.65% 165,792 $771.87
Q3 2025 -15,974 Reduce 9.95% 144,607 $562.27
Q2 2025 +45,701 Add 39.78% 160,581 $525.00
Q1 2025 +114,880 New Buy 114,880 $634.23

Mason Hawkins's Regeneron Pharmaceuticals Investment FAQs

Mason Hawkins first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q1 2025, acquiring 114,880 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Mason Hawkins has held Regeneron Pharmaceuticals, Inc. (REGN) for 5 quarters since Q1 2025.

Mason Hawkins's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q1 2025, adding 114,880 shares worth $72.86 M.

According to the latest 13F filing for Q1 2026, Mason Hawkins's firm, Southeastern Asset Management Inc/Tn/, owns 130,662 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $100.95 M.

As of the Q1 2026 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 4.97% of Mason Hawkins's publicly disclosed stock portfolio, making it one of their key holdings.

Mason Hawkins's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 165,792 shares, as reported at the end of Q4 2025.